25 XP   0   0   10

Excelsior Biopharma
Buy, Hold or Sell?

Let's analyse Excelsior Biopharma together

PenkeI guess you are interested in Excelsior Biopharma. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Excelsior Biopharma. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Excelsior Biopharma

I send you an email if I find something interesting about Excelsior Biopharma.

Quick analysis of Excelsior Biopharma (30 sec.)










What can you expect buying and holding a share of Excelsior Biopharma? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
35.7%

What is your share worth?

Current worth
NT$23.50
Expected worth in 1 year
NT$21.31
How sure are you?
57.1%

+ What do you gain per year?

Total Gains per Share
NT$-2.19
Return On Investment
-7.9%

For what price can you sell your share?

Current Price per Share
NT$27.70
Expected price per share
NT$27.60 - NT$28.45
How sure are you?
50%

1. Valuation of Excelsior Biopharma (5 min.)




Live pricePrice per Share (EOD)

NT$27.70

Intrinsic Value Per Share

NT$-102.57 - NT$-123.22

Total Value Per Share

NT$-79.07 - NT$-99.71

2. Growth of Excelsior Biopharma (5 min.)




Is Excelsior Biopharma growing?

Current yearPrevious yearGrowGrow %
How rich?$33.9m$36.8m-$2.1m-6.3%

How much money is Excelsior Biopharma making?

Current yearPrevious yearGrowGrow %
Making money-$698.5k-$259k-$439.4k-62.9%
Net Profit Margin-12.2%-5.1%--

How much money comes from the company's main activities?

3. Financial Health of Excelsior Biopharma (5 min.)




What can you expect buying and holding a share of Excelsior Biopharma? (5 min.)

Welcome investor! Excelsior Biopharma's management wants to use your money to grow the business. In return you get a share of Excelsior Biopharma.

What can you expect buying and holding a share of Excelsior Biopharma?

First you should know what it really means to hold a share of Excelsior Biopharma. And how you can make/lose money.

Speculation

The Price per Share of Excelsior Biopharma is NT$27.70. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Excelsior Biopharma.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Excelsior Biopharma, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$23.50. Based on the TTM, the Book Value Change Per Share is NT$-0.55 per quarter. Based on the YOY, the Book Value Change Per Share is NT$-0.12 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Excelsior Biopharma.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.000.0%-0.01-0.1%-0.010.0%-0.010.0%-0.010.0%
Usd Book Value Change Per Share0.020.1%-0.02-0.1%0.000.0%0.050.2%0.050.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.020.1%-0.02-0.1%0.000.0%0.060.2%0.060.2%
Usd Price Per Share0.89-0.92-0.86-0.89-0.89-
Price to Earnings Ratio54.28-4.96--94.95--25.73--25.73-
Price-to-Total Gains Ratio49.98--15.42-3,015.48-867.66-867.66-
Price to Book Ratio1.23-1.25-1.09-1.13-1.13-
Price-to-Total Gains Ratio49.98--15.42-3,015.48-867.66-867.66-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.85039
Number of shares1175
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.020.05
Usd Total Gains Per Share-0.020.06
Gains per Quarter (1175 shares)-19.7773.36
Gains per Year (1175 shares)-79.06293.42
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-79-8951242283
20-158-168102484576
30-237-247154727869
40-316-3262059691162
50-395-40525612111455
60-474-48430714531748
70-553-56335816962041
80-632-64240919382334
90-712-72146121802627
100-791-80051224222920

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%4.010.00.028.6%4.010.00.028.6%4.010.00.028.6%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%5.09.00.035.7%5.09.00.035.7%5.09.00.035.7%
Dividend per Share0.00.04.00.0%3.00.09.025.0%5.00.09.035.7%5.00.09.035.7%5.00.09.035.7%
Total Gains per Share1.03.00.025.0%6.06.00.050.0%8.06.00.057.1%8.06.00.057.1%8.06.00.057.1%

Fundamentals of Excelsior Biopharma

About Excelsior Biopharma

Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases. It also offers test kits under the Actim name to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking. In addition, the company provides toothpaste, and mouth wash and gel products under the Oral7 name; and food and medical beauty maintenance products. Further, it imports and exports active pharmaceutical ingredients; and engages in the research of technologies, and pharmaceutical technologies transfer and cooperative development and improvement activities. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was incorporated in 1988 and is headquartered in Taipei, Taiwan.

Fundamental data was last updated by Penke on 2024-04-20 16:44:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Excelsior Biopharma.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Excelsior Biopharma earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Excelsior Biopharma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 3.0% means that NT$0.03 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Excelsior Biopharma:

  • The MRQ is 3.0%. The company is making a profit. +1
  • The TTM is -12.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ3.0%TTM-12.2%+15.2%
TTM-12.2%YOY-5.1%-7.2%
TTM-12.2%5Y-5.1%-7.2%
5Y-5.1%10Y-5.1%0.0%
1.1.2. Return on Assets

Shows how efficient Excelsior Biopharma is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Excelsior Biopharma to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.4% Return on Assets means that Excelsior Biopharma generated NT$0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Excelsior Biopharma:

  • The MRQ is 0.4%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -1.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-1.3%+1.7%
TTM-1.3%YOY-0.5%-0.8%
TTM-1.3%5Y-0.5%-0.8%
5Y-0.5%10Y-0.5%0.0%
1.1.3. Return on Equity

Shows how efficient Excelsior Biopharma is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Excelsior Biopharma to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.6% Return on Equity means Excelsior Biopharma generated NT$0.01 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Excelsior Biopharma:

  • The MRQ is 0.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -2.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.6%TTM-2.0%+2.6%
TTM-2.0%YOY-0.7%-1.3%
TTM-2.0%5Y-0.8%-1.2%
5Y-0.8%10Y-0.8%0.0%

1.2. Operating Efficiency of Excelsior Biopharma.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Excelsior Biopharma is operating .

  • Measures how much profit Excelsior Biopharma makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Excelsior Biopharma to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Excelsior Biopharma:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-4.4%+4.4%
TTM-5Y-1.3%+1.3%
5Y-1.3%10Y-1.3%0.0%
1.2.2. Operating Ratio

Measures how efficient Excelsior Biopharma is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.51 means that the operating costs are NT$1.51 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Excelsior Biopharma:

  • The MRQ is 1.507. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.712. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.507TTM1.712-0.205
TTM1.712YOY1.622+0.090
TTM1.7125Y1.718-0.007
5Y1.71810Y1.7180.000

1.3. Liquidity of Excelsior Biopharma.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Excelsior Biopharma is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 5.92 means the company has NT$5.92 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Excelsior Biopharma:

  • The MRQ is 5.918. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.679. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.918TTM3.679+2.239
TTM3.679YOY6.266-2.587
TTM3.6795Y5.332-1.653
5Y5.33210Y5.3320.000
1.3.2. Quick Ratio

Measures if Excelsior Biopharma is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Excelsior Biopharma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.93 means the company can pay off NT$0.93 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Excelsior Biopharma:

  • The MRQ is 0.930. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.702. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.930TTM0.702+0.228
TTM0.702YOY1.439-0.737
TTM0.7025Y0.935-0.233
5Y0.93510Y0.9350.000

1.4. Solvency of Excelsior Biopharma.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Excelsior Biopharma assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Excelsior Biopharma to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.30 means that Excelsior Biopharma assets are financed with 30.0% credit (debt) and the remaining percentage (100% - 30.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Excelsior Biopharma:

  • The MRQ is 0.300. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.334. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.300TTM0.334-0.034
TTM0.334YOY0.296+0.038
TTM0.3345Y0.324+0.010
5Y0.32410Y0.3240.000
1.4.2. Debt to Equity Ratio

Measures if Excelsior Biopharma is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Excelsior Biopharma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 42.8% means that company has NT$0.43 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Excelsior Biopharma:

  • The MRQ is 0.428. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.512. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.428TTM0.512-0.084
TTM0.512YOY0.420+0.092
TTM0.5125Y0.483+0.029
5Y0.48310Y0.4830.000

2. Market Valuation of Excelsior Biopharma

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Excelsior Biopharma generates.

  • Above 15 is considered overpriced but always compare Excelsior Biopharma to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 54.28 means the investor is paying NT$54.28 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Excelsior Biopharma:

  • The EOD is 52.114. Based on the earnings, the company is expensive. -2
  • The MRQ is 54.278. Based on the earnings, the company is expensive. -2
  • The TTM is 4.959. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD52.114MRQ54.278-2.164
MRQ54.278TTM4.959+49.319
TTM4.959YOY-94.950+99.909
TTM4.9595Y-25.734+30.693
5Y-25.73410Y-25.7340.000
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Excelsior Biopharma:

  • The EOD is -6.193. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.450. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.708. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.193MRQ-6.450+0.257
MRQ-6.450TTM-8.708+2.258
TTM-8.708YOY-50.428+41.721
TTM-8.7085Y-12.492+3.784
5Y-12.49210Y-12.4920.000
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Excelsior Biopharma is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.23 means the investor is paying NT$1.23 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Excelsior Biopharma:

  • The EOD is 1.179. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.227. Based on the equity, the company is underpriced. +1
  • The TTM is 1.253. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.179MRQ1.227-0.049
MRQ1.227TTM1.253-0.026
TTM1.253YOY1.091+0.162
TTM1.2535Y1.126+0.127
5Y1.12610Y1.1260.000
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Excelsior Biopharma compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.577-0.548+195%-0.121+121%1.679-66%1.679-66%
Book Value Per Share--23.50423.958-2%25.574-8%25.815-9%25.815-9%
Current Ratio--5.9183.679+61%6.266-6%5.332+11%5.332+11%
Debt To Asset Ratio--0.3000.334-10%0.296+1%0.324-7%0.324-7%
Debt To Equity Ratio--0.4280.512-16%0.420+2%0.483-11%0.483-11%
Dividend Per Share----0%-0%0.355-100%0.355-100%
Eps--0.133-0.481+462%-0.180+235%-0.194+246%-0.194+246%
Free Cash Flow Per Share---1.118-0.904-19%-0.012-99%-0.071-94%-0.071-94%
Free Cash Flow To Equity Per Share---1.118-0.904-19%-0.085-92%0.159-803%0.159-803%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---123.216--------
Intrinsic Value_10Y_min---102.570--------
Intrinsic Value_1Y_max---2.514--------
Intrinsic Value_1Y_min---2.464--------
Intrinsic Value_3Y_max---15.048--------
Intrinsic Value_3Y_min---14.214--------
Intrinsic Value_5Y_max---36.616--------
Intrinsic Value_5Y_min---33.341--------
Market Cap1301603610.000-4%1355641305.0001416312738.750-4%1311588836.250+3%1362571226.786-1%1362571226.786-1%
Net Profit Margin--0.030-0.122+510%-0.051+270%-0.051+270%-0.051+270%
Operating Margin----0%-0.0440%-0.0130%-0.0130%
Operating Ratio--1.5071.712-12%1.622-7%1.718-12%1.718-12%
Pb Ratio1.179-4%1.2271.253-2%1.091+12%1.126+9%1.126+9%
Pe Ratio52.114-4%54.2784.959+995%-94.950+275%-25.734+147%-25.734+147%
Price Per Share27.700-4%28.85030.013-4%27.913+3%28.9610%28.9610%
Price To Free Cash Flow Ratio-6.193+4%-6.450-8.708+35%-50.428+682%-12.492+94%-12.492+94%
Price To Total Gains Ratio47.986-4%49.978-15.424+131%3015.476-98%867.659-94%867.659-94%
Quick Ratio--0.9300.702+32%1.439-35%0.935-1%0.935-1%
Return On Assets--0.004-0.013+426%-0.005+225%-0.005+233%-0.005+233%
Return On Equity--0.006-0.020+455%-0.007+224%-0.008+241%-0.008+241%
Total Gains Per Share--0.577-0.548+195%-0.121+121%2.034-72%2.034-72%
Usd Book Value--33906737.80034709573.500-2%36892282.100-8%37282255.429-9%37282255.429-9%
Usd Book Value Change Per Share--0.018-0.017+195%-0.004+121%0.052-66%0.052-66%
Usd Book Value Per Share--0.7220.736-2%0.785-8%0.793-9%0.793-9%
Usd Dividend Per Share----0%-0%0.011-100%0.011-100%
Usd Eps--0.004-0.015+462%-0.006+235%-0.006+246%-0.006+246%
Usd Free Cash Flow---1613131.500-1307873.725-19%-17629.475-99%-104272.550-94%-104272.550-94%
Usd Free Cash Flow Per Share---0.034-0.028-19%0.000-99%-0.002-94%-0.002-94%
Usd Free Cash Flow To Equity Per Share---0.034-0.028-19%-0.003-92%0.005-803%0.005-803%
Usd Market Cap39959230.827-4%41618188.06443480801.080-4%40265777.273+3%41830936.662-1%41830936.662-1%
Usd Price Per Share0.850-4%0.8860.921-4%0.857+3%0.8890%0.8890%
Usd Profit--191690.800-698509.425+464%-259084.975+235%-281731.707+247%-281731.707+247%
Usd Revenue--6421457.6005921738.350+8%5155781.025+25%7660516.179-16%7660516.179-16%
Usd Total Gains Per Share--0.018-0.017+195%-0.004+121%0.062-72%0.062-72%
 EOD+3 -5MRQTTM+19 -13YOY+15 -175Y+11 -2310Y+11 -23

3.2. Fundamental Score

Let's check the fundamental score of Excelsior Biopharma based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1552.114
Price to Book Ratio (EOD)Between0-11.179
Net Profit Margin (MRQ)Greater than00.030
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.930
Current Ratio (MRQ)Greater than15.918
Debt to Asset Ratio (MRQ)Less than10.300
Debt to Equity Ratio (MRQ)Less than10.428
Return on Equity (MRQ)Greater than0.150.006
Return on Assets (MRQ)Greater than0.050.004
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Excelsior Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.968
Ma 20Greater thanMa 5028.080
Ma 50Greater thanMa 10028.269
Ma 100Greater thanMa 20028.416
OpenGreater thanClose27.850
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Net Income  -1,133-22,778-23,911-12,263-36,174-996-37,17043,4146,244
Net Income from Continuing Operations  -1,133-22,778-23,911-12,263-36,174-996-37,17043,4146,244



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets1,577,328
Total Liabilities472,874
Total Stockholder Equity1,104,454
 As reported
Total Liabilities 472,874
Total Stockholder Equity+ 1,104,454
Total Assets = 1,577,328

Assets

Total Assets1,577,328
Total Current Assets984,092
Long-term Assets593,236
Total Current Assets
Cash And Cash Equivalents 589,918
Net Receivables 154,650
Inventory 217,281
Other Current Assets 14,167
Total Current Assets  (as reported)984,092
Total Current Assets  (calculated)976,016
+/- 8,076
Long-term Assets
Property Plant Equipment 473,190
Long-term Assets  (as reported)593,236
Long-term Assets  (calculated)473,190
+/- 120,046

Liabilities & Shareholders' Equity

Total Current Liabilities166,284
Long-term Liabilities306,590
Total Stockholder Equity1,104,454
Total Current Liabilities
Short Long Term Debt 23,184
Accounts payable 22,236
Other Current Liabilities 4,802
Total Current Liabilities  (as reported)166,284
Total Current Liabilities  (calculated)50,222
+/- 116,062
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt354,221
Long-term Liabilities  (as reported)306,590
Long-term Liabilities  (calculated)354,221
+/- 47,631
Total Stockholder Equity
Retained Earnings 186,945
Total Stockholder Equity (as reported)1,104,454
Total Stockholder Equity (calculated)186,945
+/- 917,509
Other
Capital Stock477,919
Common Stock Shares Outstanding 46,989
Net Invested Capital 1,127,638
Net Working Capital 817,808
Property Plant and Equipment Gross 473,190



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
1,940,116
1,900,208
2,018,365
1,963,542
1,892,507
1,839,043
1,707,234
1,705,127
1,700,229
1,714,973
1,693,218
1,644,582
1,913,453
1,577,328
1,577,3281,913,4531,644,5821,693,2181,714,9731,700,2291,705,1271,707,2341,839,0431,892,5071,963,5422,018,3651,900,2081,940,116
   > Total Current Assets 
1,649,343
1,622,912
1,717,999
1,642,608
1,588,879
1,532,689
1,424,954
1,432,069
1,420,837
1,443,117
1,427,931
1,349,178
1,343,448
984,092
984,0921,343,4481,349,1781,427,9311,443,1171,420,8371,432,0691,424,9541,532,6891,588,8791,642,6081,717,9991,622,9121,649,343
       Cash And Cash Equivalents 
1,100,162
1,140,660
1,228,299
1,152,425
1,114,354
1,102,762
919,497
917,332
902,749
895,276
855,211
798,417
948,990
589,918
589,918948,990798,417855,211895,276902,749917,332919,4971,102,7621,114,3541,152,4251,228,2991,140,6601,100,162
       Short-term Investments 
210
11,221
11,041
11,011
11,011
0
200,000
200,000
200,000
211,187
211,187
211,187
11,187
0
011,187211,187211,187211,187200,000200,000200,000011,01111,01111,04111,221210
       Net Receivables 
215,476
190,065
200,081
204,597
194,797
214,514
126,596
120,160
136,110
137,981
148,357
141,012
145,753
154,650
154,650145,753141,012148,357137,981136,110120,160126,596214,514194,797204,597200,081190,065215,476
       Inventory 
327,860
276,476
266,084
262,668
260,680
204,600
168,940
184,550
170,888
188,579
193,886
179,679
216,982
217,281
217,281216,982179,679193,886188,579170,888184,550168,940204,600260,680262,668266,084276,476327,860
       Other Current Assets 
5,845
4,700
12,524
11,907
8,037
10,813
9,921
10,027
11,090
10,094
11,824
11,615
12,677
14,167
14,16712,67711,61511,82410,09411,09010,0279,92110,8138,03711,90712,5244,7005,845
   > Long-term Assets 
290,773
277,296
300,366
320,934
303,628
306,354
282,280
273,058
279,392
271,856
265,287
295,404
570,005
593,236
593,236570,005295,404265,287271,856279,392273,058282,280306,354303,628320,934300,366277,296290,773
       Property Plant Equipment 
212,886
214,309
207,399
200,475
194,151
188,082
179,701
174,320
172,056
167,904
163,957
183,906
463,087
473,190
473,190463,087183,906163,957167,904172,056174,320179,701188,082194,151200,475207,399214,309212,886
       Other Assets 
35,234
39,362
36,790
37,109
37,987
44,066
39,442
36,959
37,278
37,747
0
0
0
0
000037,74737,27836,95939,44244,06637,98737,10936,79039,36235,234
> Total Liabilities 
652,851
617,146
700,176
673,583
628,679
608,898
498,280
509,974
504,966
507,531
513,221
503,263
816,803
472,874
472,874816,803503,263513,221507,531504,966509,974498,280608,898628,679673,583700,176617,146652,851
   > Total Current Liabilities 
281,323
248,656
334,436
310,361
268,112
250,271
145,540
159,369
452,145
458,637
466,414
444,472
497,271
166,284
166,284497,271444,472466,414458,637452,145159,369145,540250,271268,112310,361334,436248,656281,323
       Short Long Term Debt 
16,961
21,378
13,354
20,135
15,823
32,560
14,787
21,013
315,645
322,041
310,372
327,404
19,332
23,184
23,18419,332327,404310,372322,041315,64521,01314,78732,56015,82320,13513,35421,37816,961
       Accounts payable 
164,319
128,848
228,913
159,969
151,658
121,509
35,882
51,452
35,689
63,753
76,849
26,699
47,180
22,236
22,23647,18026,69976,84963,75335,68951,45235,882121,509151,658159,969228,913128,848164,319
       Other Current Liabilities 
102,285
104,830
90,255
134,833
100,653
112,719
92,108
90,507
103,677
82,696
5,301
3,668
5,717
4,802
4,8025,7173,6685,30182,696103,67790,50792,108112,719100,653134,83390,255104,830102,285
   > Long-term Liabilities 
371,528
368,490
365,740
363,222
360,567
358,627
352,740
350,605
52,821
48,894
46,807
58,791
319,532
306,590
306,590319,53258,79146,80748,89452,821350,605352,740358,627360,567363,222365,740368,490371,528
       Long term Debt 
289,718
290,567
291,418
292,272
293,128
293,987
294,848
295,711
0
0
0
0
0
0
000000295,711294,848293,987293,128292,272291,418290,567289,718
       Capital Lease Obligations Min Short Term Debt
86,429
83,439
80,272
77,191
73,922
70,642
63,974
60,836
57,320
53,791
50,250
68,458
360,111
354,221
354,221360,11168,45850,25053,79157,32060,83663,97470,64273,92277,19180,27283,43986,429
       Other Liabilities 
7,729
7,122
6,978
6,978
6,978
7,701
7,701
7,701
7,701
5,854
0
0
0
0
00005,8547,7017,7017,7017,7016,9786,9786,9787,1227,729
> Total Stockholder Equity
1,287,265
1,283,062
1,318,189
1,289,959
1,263,828
1,230,145
1,208,954
1,195,153
1,195,263
1,207,442
1,179,997
1,141,319
1,096,650
1,104,454
1,104,4541,096,6501,141,3191,179,9971,207,4421,195,2631,195,1531,208,9541,230,1451,263,8281,289,9591,318,1891,283,0621,287,265
   Common Stock
466,670
466,670
466,670
466,670
466,670
466,670
466,670
466,670
475,070
475,070
0
0
0
0
0000475,070475,070466,670466,670466,670466,670466,670466,670466,670466,670
   Retained Earnings 
541,553
545,364
547,935
498,358
485,811
482,604
472,478
460,032
449,980
453,372
254,280
218,106
180,936
186,945
186,945180,936218,106254,280453,372449,980460,032472,478482,604485,811498,358547,935545,364541,553
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 
15,799
7,785
40,341
61,688
49,832
41,364
30,299
28,944
38,745
47,532
0
0
0
0
000047,53238,74528,94430,29941,36449,83261,68840,3417,78515,799



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue771,562
Cost of Revenue-464,632
Gross Profit306,930306,930
 
Operating Income (+$)
Gross Profit306,930
Operating Expense-851,714
Operating Income-80,152-544,784
 
Operating Expense (+$)
Research Development62,513
Selling General Administrative324,569
Selling And Marketing Expenses0
Operating Expense851,714387,082
 
Net Interest Income (+$)
Interest Income5,243
Interest Expense-6,367
Other Finance Cost-0
Net Interest Income-1,124
 
Pretax Income (+$)
Operating Income-80,152
Net Interest Income-1,124
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-81,951-80,152
EBIT - interestExpense = -6,367
-91,011
-84,644
Interest Expense6,367
Earnings Before Interest and Taxes (EBIT)0-75,584
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-81,951
Tax Provision-9,060
Net Income From Continuing Ops-91,011-91,011
Net Income-91,011
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net01,124
 

Technical Analysis of Excelsior Biopharma
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Excelsior Biopharma. The general trend of Excelsior Biopharma is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Excelsior Biopharma's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Excelsior Biopharma.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 27.70 < 27.70 < 28.45.

The bearish price targets are: 27.65 > 27.60 > 27.60.

Tweet this
Excelsior Biopharma Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Excelsior Biopharma. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Excelsior Biopharma Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Excelsior Biopharma. The current macd is -0.13093446.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Excelsior Biopharma price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Excelsior Biopharma. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Excelsior Biopharma price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Excelsior Biopharma Daily Moving Average Convergence/Divergence (MACD) ChartExcelsior Biopharma Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Excelsior Biopharma. The current adx is 22.33.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Excelsior Biopharma shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Excelsior Biopharma Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Excelsior Biopharma. The current sar is 28.88.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Excelsior Biopharma Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Excelsior Biopharma. The current rsi is 42.97. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Excelsior Biopharma Daily Relative Strength Index (RSI) ChartExcelsior Biopharma Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Excelsior Biopharma. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Excelsior Biopharma price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Excelsior Biopharma Daily Stochastic Oscillator ChartExcelsior Biopharma Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Excelsior Biopharma. The current cci is -99.43502825.

Excelsior Biopharma Daily Commodity Channel Index (CCI) ChartExcelsior Biopharma Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Excelsior Biopharma. The current cmo is -19.96421425.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Excelsior Biopharma Daily Chande Momentum Oscillator (CMO) ChartExcelsior Biopharma Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Excelsior Biopharma. The current willr is -70.21276596.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Excelsior Biopharma is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Excelsior Biopharma Daily Williams %R ChartExcelsior Biopharma Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Excelsior Biopharma.

Excelsior Biopharma Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Excelsior Biopharma. The current atr is 0.40542841.

Excelsior Biopharma Daily Average True Range (ATR) ChartExcelsior Biopharma Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Excelsior Biopharma. The current obv is 1,815,937.

Excelsior Biopharma Daily On-Balance Volume (OBV) ChartExcelsior Biopharma Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Excelsior Biopharma. The current mfi is 36.90.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Excelsior Biopharma Daily Money Flow Index (MFI) ChartExcelsior Biopharma Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Excelsior Biopharma.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-19STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-25STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Excelsior Biopharma Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Excelsior Biopharma based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.968
Ma 20Greater thanMa 5028.080
Ma 50Greater thanMa 10028.269
Ma 100Greater thanMa 20028.416
OpenGreater thanClose27.850
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Excelsior Biopharma with someone you think should read this too:
  • Are you bullish or bearish on Excelsior Biopharma? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Excelsior Biopharma? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Excelsior Biopharma

I send you an email if I find something interesting about Excelsior Biopharma.


Comments

How you think about this?

Leave a comment

Stay informed about Excelsior Biopharma.

Receive notifications about Excelsior Biopharma in your mailbox!